abacavir and lamivudine

Generic: abacavir and lamivudine

Labeler: aurobindo pharma limited
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name abacavir and lamivudine
Generic Name abacavir and lamivudine
Labeler aurobindo pharma limited
Dosage Form TABLET, FILM COATED
Routes
ORAL
Active Ingredients

abacavir sulfate 600 mg/1, lamivudine 300 mg/1

Manufacturer
Aurobindo Pharma Limited

Identifiers & Regulatory

Product NDC 65862-335
Product ID 65862-335_7fbb109d-29d0-4439-b4ef-00c587cc6099
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA090159
Listing Expiration 2026-12-31
Marketing Start 2018-11-15

Pharmacologic Class

Established (EPC)
hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc] human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]
Mechanism of Action
nucleoside reverse transcriptase inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 65862335
Hyphenated Format 65862-335

Supplemental Identifiers

RxCUI
602393
UNII
J220T4J9Q2 2T8Q726O95
NUI
N0000175656 N0000175462 N0000009947

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name abacavir and lamivudine (source: ndc)
Generic Name abacavir and lamivudine (source: ndc)
Application Number ANDA090159 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 600 mg/1
  • 300 mg/1
source: ndc
Packaging
  • 10 BLISTER PACK in 1 CARTON (65862-335-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK
  • 1 BOTTLE in 1 CARTON (65862-335-30) / 30 TABLET, FILM COATED in 1 BOTTLE
source: ndc

Packages (2)

Ingredients (2)

abacavir sulfate (600 mg/1) lamivudine (300 mg/1)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "7fbb109d-29d0-4439-b4ef-00c587cc6099", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "unii": ["J220T4J9Q2", "2T8Q726O95"], "rxcui": ["602393"], "spl_set_id": ["deda1a24-2f51-4601-9881-347f47270940"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Aurobindo Pharma Limited"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "10 BLISTER PACK in 1 CARTON (65862-335-10)  / 10 TABLET, FILM COATED in 1 BLISTER PACK", "package_ndc": "65862-335-10", "marketing_start_date": "20181115"}, {"sample": false, "description": "1 BOTTLE in 1 CARTON (65862-335-30)  / 30 TABLET, FILM COATED in 1 BOTTLE", "package_ndc": "65862-335-30", "marketing_start_date": "20181115"}], "brand_name": "Abacavir and Lamivudine", "product_id": "65862-335_7fbb109d-29d0-4439-b4ef-00c587cc6099", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Cytochrome P450 1A1 Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "65862-335", "generic_name": "Abacavir and Lamivudine", "labeler_name": "Aurobindo Pharma Limited", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Abacavir and Lamivudine", "active_ingredients": [{"name": "ABACAVIR SULFATE", "strength": "600 mg/1"}, {"name": "LAMIVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA090159", "marketing_category": "ANDA", "marketing_start_date": "20181115", "listing_expiration_date": "20261231"}